New pediatric interventional device for PAH wins ‘Shark Tank’ event at TCT 2023

Michael Walter | October 25, 2023 | Cardiovascular Business | Interventional Cardiology

HeartPoint Global Shark Tank Intellistent

Elena K. Amin, MBChB, a pediatric cardiologist with UCSF Health, poses with the winning device. Photo by Dave Fornell.

HeartPoint Global, a Florida-based healthcare technology company focused on improving patient access to high-quality technology, won the Shark Take Innovation Competition at TCT 2023 with its Intellistent multi-lumen stent system. The device, already patented in more than 20 countries, is designed to help cardiologists treat pulmonary arterial hypertension (PAH) in congenital heart disease patients by allowing for the adjustment of blood flow into the patient’s heart-lung system.

According to HeartPoint Global, the minimally invasive device was designed to deliver benefits comparable to what is typically seen with surgical treatment. It may also serve as a bridge to surgery for some cardiac patients.

“We are deeply honored to be bestowed with this prestigious award,” Seth Bogner, HeartPoint Global’s chairman and CEO, said in a prepared statement. “TCT stands as a pinnacle platform for highlighting innovation in cardiovascular medicine. Having our technology acknowledged by such a distinguished panel of judges is truly humbling. We are eager to forge ahead with HeartPoint Global's in-human trials and anticipate its substantial clinical impact in the future.”

Elena K. Amin, MBChB, a pediatric cardiologist with UCSF Health, presented her team’s data during the Shark Tank competition. Six finalists were selected to attend TCT 2023 and present their technology, and HeartPoint Global took home a $200,000 prize for winning the competition. A panel of physicians, investors and industry experts served as judges.

HeartPoint Global plans on using the technology behind the Intellistent to treat numerous other conditions in the future. Click here to read an analysis of the technology published in JACC: Basic to Translational Science, an American College of Cardiology journal.[1]

Late-breaking clinical trials at TCT 2023 could lead to FDA approvals for Abbott, Boston Scientific

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

Shockwave Medical introducing more efficient IVL catheter to US market at TCT 2023

Late-breaking clinical trials at TCT 2023

‘Massive leap forward’: 4D MRI helps diagnose prenatal congenital heart disease

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.